Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration
MELBOURNE, Australia and PALO ALTO, Calif., Dec. 11, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces a strategic clinical collaboration with Varian, a Siemens Healthineers company and global leader in radiation oncology, to develop novel clinical applications that combine Telix's theranostic products and external beam radiation therapy...
DNV RECEIVES CMS APPROVAL FOR NEW AMBULATORY SURGERY CENTERS ACCREDITATION PROGRAM
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. The new NIAHO® ASC Accreditation Program today received official...
DNV LAUNCHES ACCREDITATION FOR AMBULATORY SURGERY CENTERS
New offering builds on DNV's value-driven approach to healthcare accreditation, focusing on continuous improvement, patient safety and public health outcomes HOUSTON, Dec. 10, 2025 /PRNewswire/ -- DNV is expanding its highly regarded healthcare accreditation service to the fast-growing ambulatory surgery center (ASC) sector. Ambulatory surgery centers, also known as outpatient or day surgery...
Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals") and Formation Bio today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation Bio's newly formed subsidiary Bleecker Bio. LNK01006 recently received...
Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib’s Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+
First patient from TNBC trial demonstrated 76% tumor volume shrinkage with corresponding reductions in circulating tumor cells (CTC) and clusters Reinvigoration of immune system + turning cold tumors hot Preliminary ex-vivo data in HER2+ patients demonstrates immune reinvigoration and reductions in CTC and clusters SYDNEY, Dec. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited ("Kazia" or the "Company") (NASDAQ: KZIA) today...
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision oncology. HAMBURG, Germany and ROCHESTER, N.Y., Dec. 10, 2025 /PRNewswire/ -- Indivumed is excited to announce its partnership with the world-renowned Wilmot Cancer Institute at the University of Rochester Medical Center (URMC). Leveraging Indivumed's proven approach to standardized tissue...
World Gym Corporation (2762.TW) Reports Robust November Revenue Growth and Unveils Ambitious 2026 Strategic Roadmap
TAIPEI, Dec. 10, 2025 /PRNewswire/ -- World Gym Corp. (2762.TW), owner and operator of the iconic World Gym brand, announced consolidated revenue of NT$959,696 thousand for November 2025, representing a robust year-over-year increase of 14.24% compared to November 2024. YTD Revenue surpassed the NT$10 billion mark to reach NT$10.015 billion, an increase...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter Phase III clinical trial. HONG KONG, Dec. 10, 2025 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today that its New Drug Application (NDA) for denifanstat (ASC40), a first-in-class, once-daily...
Berlin Heals Welcomes Rob ten Hoedt as New Chairman of the Board
ZUG, Switzerland, Dec. 10, 2025 /PRNewswire/ -- Berlin Heals Holding AG (Zug, Switzerland) is pleased to announce the appointment of Rob ten Hoedt as the new Chairman of the Board of Directors. "We are thrilled to welcome someone of Rob ten Hoedt's caliber to the Board," said Marko Bagaric, Co-founder and Member of...
Stay True to Our Original Aspiration, Forge Ahead into the Future｜Alphamab Oncology 2025 R&D Day Successfully Held
SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- On December 8, 2025, Alphamab Oncology (Stock Code: 9966.HK) successfully held its "Stay True to Our Original Aspiration, Forge Ahead into the Future" 2025 R&D Day in Shanghai. The event focused on the latest advancements in the field of antibody-drug conjugates (ADCs), comprehensively showcasing the company's R&D achievements in bispecific ADCs and dual-payload...
